Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 8;12(2):125–137. doi: 10.1093/jmcb/mjz032

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) (2019). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Oxaliplatin and GSK-J4 alter NOTCH2 expression by affecting the level of H3K27me3 transcription initiation region. (A) ChIP-qPCR analysis of H3K27me3 binding to the NOTCH2 promoter in HCT116 cells. (B) ChIP-qPCR analysis of anti-H3K27me3 in control and GSK-J4 (1 μM) or oxaliplatin (50 μM)-treated cells. (C) qRT-PCR detection of KDM6A/KDM6B expression after NOTCH2 knockdown. (D) Western blot detection of NOTCH2 expression in NOTCH2 overexpression HCT116 cells (upper right panel). NOTCH2 overexpression and control HCT116 cells were treated with GSK-J4 (1 μM) and exposed to oxaliplatin (50 μM) for 48 h. The percentage of cells entering apoptosis was determined by flow cytometry using APC-labeled Annexin V and 7-AAD staining. (E) Graphic illustration of the relationship between H3K27me3 and oxaliplatin resistance.